Evidence map›Paper›PMID 40819861›Full record

ArticleBMJ open2025

Exposure to suppressive antibiotic therapy in women with recurrent urinary tract infections and severity of infections: a retrospective population-based cohort study.

Carl Llor, Dan Ouchi, Silvia Fernández-García, Maria Giner-Soriano, Ana Moragas, Rosa Morros

Abstract read
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Carl LlorIDIAP Jordi Gol, Barcelona, Spain cllor@health.sdu.dk.ORCID http://orcid.org/0000-0001-6644-717X
Dan OuchiIDIAP Jordi Gol, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8630-152X
Silvia Fernández-GarcíaIDIAP Jordi Gol, Barcelona, Spain.
Maria Giner-SorianoMedicines Research Unit, IDIAP Jordi Gol, Barcelona, Catalunya, Spain.ORCID http://orcid.org/0000-0003-3750-9233
Ana MoragasPrimary Healthcare Centre Jaume I, Tarragona, Spain, Universitat Rovira i Virgili, Tarragona, Catalunya, Spain.
Rosa MorrosMedicines Research Unit, IDIAP Jordi Gol, Barcelona, Catalunya, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWomen with recurrent urinary tract infections (UTIs) often undergo intensive antibiotic exposure, especially with suppressive therapies. Suppressive therapy is recommended for women with three UTIs in the past year or two in the last 6 months. However, the collateral long-term effects of this have been poorly studied.

objectivesTo assess whether suppressive therapy for recurrent UTIs increases the incidence and severity of future infections compared with episodic UTI treatment.

designRetrospective cohort study. SETTING AND

participantsThe study was conducted using data from the Information System for Research in Primary Care database, including 5.8 million people in Catalonia. Two groups of women with recurrent UTIs (≥3 episodes/year) were compared: those on suppressive antibiotic therapy for ≥6 months and those treated episodically. Primary outcomes were hospitalisations due to pyelonephritis, septicaemia, COVID-19, influenza, pneumonia and mortality by these infections, over a 100-month follow-up period.

resultsAmong 36 170 women, 2898 (8%) were treated with continuous suppressive therapy. Overall, 6.9% of the population experienced severe infections, with a higher incidence in women on suppressive therapy (12.6%) compared with those without (6.4%), with a HR of 1.50 (95% CI 1.33 to 1.68). Pyelonephritis presented the greatest difference (HR, 1.95 (95% CI 1.64 to 2.33)), followed by septicaemia (HR, 1.34 (95% CI 1.13 to 1.59)) and COVID-19 (HR 1.23 (95% CI 1.01 to 1.50)).

conclusionsSuppressive antibiotic therapy in women with recurrent UTIs is associated with a higher incidence and severity of future infections. Future research should focus on clarifying causal relationships and identifying the potential mechanisms involved.

Indexed as

Anti-Bacterial AgentsUrinary Tract InfectionsAdultAgedCOVID-19FemaleHospitalizationHumansIncidenceMiddle AgedRecurrenceRetrospective StudiesSeverity of Illness IndexSpainAnti-Bacterial AgentsAnti-Bacterial AgentsCOVID-19PrognosisUrinary tract infections

Identifiers

PMID40819861
PMCPMC12359520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.